Good MorningEquities moved higher on Wednesday despite a hot reading of the CPI. The CPI came in at 0.5% for the month or up a tenth hotter than expected with similar strength at the core and YOY levels. The takeaway is that inflation continues to rise and is leaving the FOMC no choice but to raise rates. Based on Jerome Powell’s testimony to Congress it looks like the Fed will be raising rates at a much quicker pace than ever indicated. According to the CME’s FedWath Tool, a rate hike is all but assured at the March FOMC meeting.
Today’s action will be driven by the PPI. The Producer Price Index is expected to subside from the previous month but could easily come in hotter than expected. Even so, with CPI already at record levels, a cool read on the PPI will do little to alter the outlook. The question is how will the market react?
Featured: Elon’s big $266,000 per second purchase (Ad) 
|
Consumer Staples | |
Energy drink maker Monster Beverage (NASDAQ: MNST) shares have been rallying despite the market sell-off on merger speculation. The rising costs of aluminum, shipping costs and supply chain disruptions hurt margins resulting in a miss on in its Q3 2021 earnings report. While the Company doesn&rsqu... Read the Full Story |
|
From Our Partners | | Bill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97.
It's a single-page, seven-point filter designed to help traders identify weak setups before placing any options trade. Print it, keep it at your desk, and run it before every trade. The download link expires soon. | | Download your free copy of the Smart Trade Options Checklist now |
|
Technology | |
Consider Adding These 3 Stocks Trading Under $100
One of the most attractive qualities of the stock market is that you don’t necessarily have to be a big spender in order to capitalize on the potential for long-term gains. Quality companies are priced at all different levels, and investors ... Read the Full Story |
|
Markets | |
There's no secret that real estate was a dizzying rollercoaster in 2021. If you didn't dip into real estate investing last year, here's a quick summary of what happened:
The pandemic completely bent the home-buying process last year. Low mortgage interest rates combined with an inventory shortag... Read the Full Story |
|
From Our Partners | | Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 is orchestrating what analyst Porter Stansberry calls a total U.S. money reset, bypassing conventional legal channels under the guise of national security.
The last time America reset its currency - under Nixon in the 1970s - it created an average of 1,300 new millionaires a day for over 50 years. Stansberry has identified three asset categories connected to Trump's initiative that could surge, plus his single top investment move. | | Watch the documentary briefing and find out which side you land on |
|
Markets | |
Since 2011, MarketBeat has made it our mission to give individual investors a way to level the playing field with institutional investors. We noticed there was a lack of high-quality stock research tools for investors of all levels. And even if there was, there was no place for investors to go as ... Read the Full Story |
|
Consumer Discretionary | |
The Rebound In Lululemon Athletica Is On
After falling more than 31% from the all-time high set in late 2021 shares of Lululemon Athletica (NASDAQ: LULU) are ready to rebound. The market caved in the wake of the updated Q4 guidance and may move lower but we don’t think so. The market caved ... Read the Full Story |
|
From Our Partners | | Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now.
Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen.
Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch. | | Watch how to access the legal backdoor before it closes. |
|
Consumer Staples | |
Albertsons Slips After Strong Earnings, Upward Guidance
Albertsons Companies (NYSE: ACI) has been working hard on improving its business over the past year or two and those efforts are showing up in the results. The company reported better than expected earnings for FQ3 and gave favorable guidanc... Read the Full Story |
|
Markets | |
Accolade, Inc Is Poised For A Major Rebound
Accolade, Inc (NASDAQ: ACCD) caught our attention last year after it IPOd. The company is a business-services provider that offers a cloud-based platform that helps employees understand and utilize their healthcare benefits. The company’s revenue... Read the Full Story |
|
Consumer Discretionary | |
The glory days appear to be over for Roku (NASDAQ: ROKU) shareholders. After the digital media device maker’s stock price twice climb to nearly $500, it’s been a horror show on the way down. Last week Roku fell to a fresh 52-week low and more than 60% from its July 2021 peak.
While so... Read the Full Story |
|
Markets | |
Adaptive network solutions provider Ciena Corporation (NYSE: CIEN) stock exploded higher on its fiscal Q4 2021 earnings release hitting multi-year highs. The optical fiber leader is benefitting from the 5G buildout and digital transformation among the 30 largest global carriers. The Company is exp... Read the Full Story |
|
Medical | |
OrganiGram Gave The Market What It Wanted
We were only interested in one thing, really, when it came to OrganiGram’s (NASDAQ: OGI) FQ1 performance and that was profitability. We weren’t expecting the company to turn a profit but we wanted news on when it might be profitable because t... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey. | | View Today's Stock Pick |
|
